Federal regulators are looking into a multibillion-dollar class of diabetes drugs after recent reports that they could be linked to pancreatic cancer. Peter Landers reports on The News Hub.
Video - FDA Launches Rare Review Into Diabetes Drugs - WSJ.com: ". . . Facing growing evidence that some of America's top-selling diabetes medicines could lead to pancreatic disease, federal regulators on Thursday opened an unusual review of drugs from Merck & Co., Bristol-Myers Squibb Co. and other pharmaceutical makers. The Food and Drug Administration said it was asking researchers for more information about how the drugs, used to treat type-2 diabetes, could lead to inflammation of the pancreas and cause precancerous changes in cells. However, the FDA stressed it hasn't concluded that the medicines "may cause or contribute to the development of pancreatic cancer.". . . . "
more news below
